← Leaderboards
Susan Buchbinder
Public Health Foundation Enterprises
$45,487,440
Attributed
$57,793,787
Total exposure
17
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$57,793,787 · 17
By mechanism
UM1$27,299,632 · 1
U01$16,055,215 · 2
R01$13,703,298 · 5
R34$521,875 · 1
M01$213,767 · 8
Top collaborators
- Diane V Havlir15 shared
- Steven L Batki2 shared
Most similar at Public Health Foundation Enterprises
Same institution · by research overlap
- Albert Ying-Hwa Liu$5,281,111
- Jonathan D. Fuchs$2,709,296
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsSan FranciscoMen Who Have Sex With MenCommunitiesPreventionPersonsPrevention StrategyUnited StatesEpidemicAids PreventionInfectionPreventResearch PersonnelMentorshipProtocols DocumentationLeadershipEnrollmentClinical TrialsHiv VaccineAdherenceHiv DiagnosisAreaAnti-Retroviral AgentsClinical Research
Grant awards (63)
San Francisco Bay Clinical Trials Unit (CTU)$1,477,862
UM1 · FY2025 · AI · contact PI
San Francisco Bay Clinical Trials Unit (CTU)$1,093,620
UM1 · FY2025 · AI · contact PI
San Francisco Bay Clinical Trials Unit (CTU)$1,415,883
UM1 · FY2024 · AI · contact PI
San Francisco Bay Clinical Trials Unit (CTU)$52,356
UM1 · FY2024 · AI · contact PI
San Francisco Bay Clinical Trials Unit (CTU)$1,415,682
UM1 · FY2023 · AI · contact PI
MyPrEP Plus: Development and Pilot Testing of Novel Pre-Exposure Prophylaxis Support Tools for Transgender Women$521,875
R34 · FY2023 · MH · contact PI
PrEP-3D: An Integrated Pharmacy Digital Diary and Delivery Strategy to Increase PrEP Use Among MSM$471,332
R01 · FY2023 · MH · contact PI
San Francisco Bay Clinical Trials Unit (CTU)$1,511,389
UM1 · FY2022 · AI · contact PI
PrEP-3D: An Integrated Pharmacy Digital Diary and Delivery Strategy to Increase PrEP Use Among MSM$495,258
R01 · FY2022 · MH · contact PI
San Francisco Bay Clinical Trials Unit (CTU)$1,347,336
UM1 · FY2021 · AI · contact PI
PrEP-3D: An Integrated Pharmacy Digital Diary and Delivery Strategy to Increase PrEP Use Among MSM$496,981
R01 · FY2021 · MH · contact PI
San Francisco Bay Clinical Trials Unit$1,934,121
UM1 · FY2020 · AI · contact PI
San Francisco Bay Clinical Trial Unit: Expanding COVID-19 Testing in Heavily Impacted Communities in San Francisco$600,000
UM1 · FY2020 · AI · contact PI
PrEP-3D: An Integrated Pharmacy Digital Diary and Delivery Strategy to Increase PrEP Use Among MSM$485,572
R01 · FY2020 · MH · contact PI
San Francisco Bay Clinical Trials Unit$2,634,428
UM1 · FY2019 · AI · contact PI
PrEP-3D: An Integrated Pharmacy Digital Diary and Delivery Strategy to Increase PrEP Use Among MSM$497,870
R01 · FY2019 · MH · contact PI
San Francisco Bay Clinical Trials Unit$1,493,196
UM1 · FY2018 · AI · contact PI
DOT Diary (D2): Developing a mobile app with combined automated DOT and daily sexual diary for monitoring and improving PrEP adherence$760,876
R01 · FY2018 · MH · contact PI
San Francisco Bay Clinical Trials Unit$1,490,310
UM1 · FY2017 · AI · contact PI
DOT Diary (D2): Developing a mobile app with combined automated DOT and daily sexual diary for monitoring and improving PrEP adherence$992,570
R01 · FY2017 · MH · contact PI
San Francisco Bay Clinical Trials Unit$1,388,627
UM1 · FY2016 · AI · contact PI
DOT Diary (D2): Developing a mobile app with combined automated DOT and daily sexual diary for monitoring and improving PrEP adherence$861,189
R01 · FY2016 · MH · contact PI
HOME: A Comprehensive HIV Testing and Linkage Package for Young MSM of Color$547,518
R01 · FY2016 · AI · contact PI
DOT Diary (D2): Developing a mobile app with combined automated DOT and daily sexual diary for monitoring and improving PrEP adherence$184,571
R01 · FY2016 · MH · contact PI
San Francisco Bay Clinical Trials Unit$1,364,094
UM1 · FY2015 · AI · contact PI
DOT Diary (D2): Developing a mobile app with combined automated DOT and daily sexual diary for monitoring and improving PrEP adherence$1,079,742
R01 · FY2015 · MH · contact PI
HOME: A Comprehensive HIV Testing and Linkage Package for Young MSM of Color$547,677
R01 · FY2015 · AI · contact PI
San Francisco Bay Clinical Trials Unit$4,418,930
UM1 · FY2014 · AI · contact PI
HOME: A Comprehensive HIV Testing and Linkage Package for Young MSM of Color$550,060
R01 · FY2014 · AI · contact PI
San Francisco Vaccine and Prevention Unit$2,287,238
UM1 · FY2013 · AI · contact PI
Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B$531,920
R01 · FY2013 · DA · contact PI
HOME: A Comprehensive HIV Testing and Linkage Package for Young MSM of Color$525,299
R01 · FY2013 · AI · contact PI
San Francisco Vaccine and Prevention Unit$1,374,560
UM1 · FY2012 · AI · contact PI
Prevention Umbrella for MSM in the Americas$610,604
R01 · FY2012 · AI · contact PI
HOME: A Comprehensive HIV Testing and Linkage Package for Young MSM of Color$569,478
R01 · FY2012 · AI · contact PI
San Francisco Vaccine and Prevention Unit$1,397,615
U01 · FY2011 · AI · contact PI
Prevention Umbrella for MSM in the Americas$1,323,041
R01 · FY2011 · AI · contact PI
Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B$442,940
R01 · FY2011 · DA · contact PI
Prevention Umbrella for MSM in the Americas$983,589
R01 · FY2010 · AI · contact PI
San Francisco Vaccine and Prevention Unit$479,197
U01 · FY2010 · AI · contact PI
San Francisco Vaccine and Prevention Unit$2,521,856
U01 · FY2009 · AI · contact PI
San Francisco Vaccine and Prevention Unit$1,443,925
U01 · FY2009 · AI · contact PI
Prevention Umbrella for MSM in the Americas$745,211
R01 · FY2009 · AI · contact PI
San Francisco Vaccine and Prevention Unit$73,048
U01 · FY2009 · AI · contact PI
San Francisco Vaccine and Prevention Unit$663,630
U01 · FY2008 · AI · contact PI
San Francisco Vaccine and Prevention Unit$754,339
U01 · FY2007 · AI · contact PI
SAN FRANCISCO HIV VACCINE CLINICAL TRAILS UNIT$392,638
U01 · FY2006 · AI · contact PI
SAN FRANCISCO HIV VACCINE CLINICAL TRAILS UNIT$1,650,506
U01 · FY2005 · AI
HVTN PROTOCOL 042/ANRS VAC019, VERSION 1: A PHASE I/II CLINICAL TRIAL$67,343
M01 · FY2005 · RR
HVTN PROTOCOL 056, VERSION 1: A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY AN$42,857
M01 · FY2005 · RR
HVTN 052: HIV-1 DNA PLASMID VACCINE AT 2 DIFFERENT DOSINGS IN HIV-1-UNINFECTED A$35,510
M01 · FY2005 · RR
HVTN 050/MERCK 018SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MRKAD5 HIV-1 GAG V$8,570
M01 · FY2005 · RR
HVTN 057: A PHASE I CLINICAL TRIAL TO EVALUATE THE SAFETY OF A MULTICLADE REC$8,570
M01 · FY2005 · RR
PHASE II EXTENDED SAFETY STUDY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) AMONG H$4,897
M01 · FY2005 · RR
SAN FRANCISCO HIV VACCINE CLINICAL TRAILS UNIT$1,404,774
U01 · FY2004 · AI
HIV-1 PGA2/JS2 PLASMID DNA VACCINE IN HIV-1 UNINFECTED ADULTS$19,887
M01 · FY2004 · RR
SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MRKAD5 HIV-1 GAG VACCINE$15,151
M01 · FY2004 · RR
HIV-1 DNA PLASMID VACCINE AT 2 DIFFERENT DOSINGS IN HIV-1-UNINFECTED ADULTS$10,418
M01 · FY2004 · RR
SAN FRANCISCO HIV VACCINE CLINICAL TRAILS UNIT$1,373,041
U01 · FY2003 · AI
SAN FRANCISCO HIV VACCINE CLINICAL TRAILS UNIT$1,334,433
U01 · FY2002 · AI
SAN FRANCISCO HIV VACCINE CLINICAL TRAILS UNIT$1,295,930
U01 · FY2001 · AI
SAN FRANCISCO HIV VACCINE CLINICAL TRAILS UNIT$1,270,283
U01 · FY2000 · AI
TRIAL OF LIVE (PRIVATE) RECOMBINANT CANARYPOX ALVA-HIV VCP205 IN HIV$564
M01 · FY2000 · RR